Welcome to our dedicated page for Immunome SEC filings (Ticker: IMNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunome, Inc. filings document the company’s targeted oncology business, public-company governance, capital structure, and material event disclosures. Its 8-K reports cover operating results, business updates, clinical and regulatory communications for programs such as varegacestat and IM-1021, investor presentations, and equity financing activity involving its common stock.
Proxy materials describe board matters, stockholder voting items, executive compensation, equity plans, and governance practices. The filing record also reflects Nasdaq-listed common stock, stock-based compensation arrangements, and formal disclosures tied to the development of antibody-drug conjugates, gamma secretase inhibition, and FAP-targeted radiotherapy within Immunome’s oncology pipeline.
Immunome, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 9, 2026. As of the April 16, 2026 record date, 113,249,519 shares of common stock were outstanding and entitled to vote.
Stockholders elected three Class III directors to serve until the 2029 Annual Meeting: James Boylan, Sandra Swain, M.D., and Philip Wagenheim. For example, Sandra Swain received 92,157,301 votes for and 224,265 votes withheld, with 11,768,578 broker non-votes.
Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 104,100,900 votes for, 27,134 against, and 22,110 abstentions. An advisory vote approved named executive officer compensation, with 90,908,436 votes for and 1,442,116 against. In a separate advisory vote on frequency, stockholders indicated a preference for annual say-on-pay votes, and the company will hold future advisory compensation votes every year in line with that preference.
Immunome Inc. director Jean Jacques Bienaimé reported offsetting trades in the company’s common stock on June 5, 2026. He made open-market purchases totaling 10,500 shares at prices between $19.27 and $19.48 per share and open-market sales totaling 10,500 shares at prices around $19.41–$19.44 per share, resulting in no net change in shares.
Following these transactions, he directly owned 43,415 shares of Immunome common stock. A footnote states that the sales were matchable with a 1,000‑share purchase under Section 16(b), and he agreed to pay $155 to Immunome, representing the full profit from that short-swing transaction.
Immunome Inc. director Jean Jacques Bienaime bought additional shares of the company’s stock. On May 15, 2026, he made an open-market purchase of 5,000 shares of Immunome common stock at a weighted average price of $20.70 per share.
The filing notes that individual trade prices ranged from $20.645 to $20.72 per share. Following this transaction, Bienaime directly holds 43,415 shares of Immunome common stock, reflecting a modest increase in his personal stake.
Immunome Inc. filing an Amendment (Schedule 13G/A) reports that Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen each report beneficial ownership of 0% of Immunome common stock as of the close of business on March 31, 2026. The amendment states the reporting persons have no sole or shared voting or dispositive power over any shares reported on that date.
Immunome, Inc. Schedule 13G/A reports that Redmile Group, LLC and Jeremy C. Green each beneficially hold 5,558,885 shares of common stock, representing 4.9% of the class based on 113,133,199 shares outstanding as of February 27, 2026. The filing states these shares are owned by Redmile-managed investment vehicles and that both Redmile and Mr. Green disclaim direct beneficial ownership except for any pecuniary interest. The ownership figures are presented as of March 31, 2026 and the schedule is signed on May 15, 2026.
T. Rowe Price Investment Management, Inc. reported beneficial ownership of 16,364,011 shares of Immunome Inc. common stock, representing 14.5% of the class. The filing (Amendment No. 1) lists voting and dispositive powers and identifies T. Rowe Price Small-Cap Stock Fund as holding 5,764,704 shares (5.2%). Signature dated 05/15/2026 appears on the amendment; a date of 03/31/2026 is shown near the cover. The filing states the adviser acts on behalf of clients and disclaims beneficial ownership on its own behalf.
Immunome Inc. reporting persons Sirenia Capital Management and Alex Silverstein reported beneficial ownership of 6,895,000 shares of common stock, representing 6.1% of the class based on 113,133,199 shares outstanding as of February 27, 2026. The holdings are shown as shared voting and dispositive power. The filing is a Schedule 13G joint statement filed under Rule 13d-1(k).
Immunome, Inc. reported a larger net loss as it accelerated investment in its oncology pipeline but ended the quarter with substantial cash. For the three months ended March 31, 2026, net loss was $53.8 million versus $41.6 million a year earlier, driven mainly by higher research and development spending of $46.4 million and general and administrative expenses of $13.0 million. There was no collaboration revenue, compared with $2.9 million in the prior-year period, after the AbbVie agreement ended in 2025.
Cash and cash equivalents were $582.7 million as of March 31, 2026, supported by 2025 equity raises and an at-the-market program, which management expects will fund operations for at least 12 months from the report filing date. The company advanced several key programs: it submitted a new drug application for desmoid tumor candidate varegacestat, received IND clearance for ADC IM-1617, initiated a Phase 1 trial for radioligand therapy IM-3050, and continues Phase 1 development of ADC IM-1021 and IND-enabling work on preclinical ADCs IM-1340 and IM-1335.
Immunome, Inc. reported first quarter 2026 results and highlighted major advances in its oncology pipeline. For the quarter ended March 31, 2026, the company recorded a net loss of $53.8 million, or $0.48 per share, compared with a net loss of $41.6 million a year earlier, as research and development expenses rose to $46.4 million. Cash and cash equivalents were $582.7 million, which the company believes can fund operations into 2028.
Strategically, Immunome submitted a New Drug Application to the U.S. FDA in April 2026 for varegacestat in adults with desmoid tumors, following the Phase 3 RINGSIDE trial. That trial showed an 84% reduction in the risk of disease progression or death versus placebo, with a hazard ratio of 0.16 and objective response rate of 56% vs. 9%. The company also advanced multiple antibody-drug conjugate programs, with IM-1021 in Phase 1, IM-3050 initiating Phase 1, and IM-1617 receiving IND clearance.